<DOC>
	<DOCNO>NCT02951221</DOCNO>
	<brief_summary>The primary objective study assess relative bioavailability BIIB074 direct compression formulation ( DCF ) BIIB074 roller compaction formulation ( RCF ) determine effect high-fat meal pharmacokinetics ( PK ) BIIB074 DCF . The secondary objective study assess safety tolerability BIIB074 administer DCF follow single oral dose administration healthy participant .</brief_summary>
	<brief_title>New Formulation Food Effect Study BIIB074</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Trigeminal Neuralgia</mesh_term>
	<criteria>Key Must body mass index 18 30 kg/m2 , inclusive . Must good health determine Investigator , base medical history screening evaluation . Ability consume tolerate entire highfat breakfast within 30minute timeframe . Key History , positive test result Screening , human immunodeficiency virus ( HIV ) . Positive test result Screening hepatitis C virus antibody . Positive test result Screening hepatitis B virus ( define positive hepatitis B surface antigen and/or hepatitis B core antibody ) . Previous exposure BIIB074 . Consumption xanthine/caffeinecontaining product ( e.g. , energy drink , coffee , tea , caffeinated soda ) within 48 hour Day 1 unwillingness refrain product use study participation . History alcohol substance abuse ( determine Investigator ) , positive urine drug screen alcohol breath test Screening Day 1 , unwillingness refrain alcohol , illicit recreational drug , study . History evidence habitual use tobacco nicotinecontaining product within 90 day Screening , positive cotinine screen Screening Day 1 . Note : Other protocol define Inclusion/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>